Suggested remit: To appraise the clinical and cost effectiveness of sacituzumab govitecan within its marketing authorisation for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies.
 
Status In progress
Technology type Medicine
Decision Selected
Process TA
ID number 4033

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
21 November 2022 As you will be aware the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Sacituzumab govitecan within its marketing authorisation for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies. Please note that following on from advice received from the company the timelines for this appraisal are to be confirmed. The appraisal will be rescheduled to align with latest regulatory expectations and an update on the revised timelines will be provided when further information is available.
09 June 2022 - 07 July 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
28 January 2022 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual